9
Views
2
CrossRef citations to date
0
Altmetric
Original Article

Phase I-II Trial of High-Dose Melphalan in Previously Untreated Stage III Multiple Myeloma: Cancer and Leukemia Group B Study 8512

Original Article

, , &
Pages 11-17 | Published online: 11 Jun 2009

References

  • Alexanian R, Bonnert J, Gehan E. Combination chemotherapy for multiple myeloma. Cancer 1972; 30: 382–389
  • Alexanian R, Haut A, Khan A. Treatment for multiple myeloma-combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208: 1680–1685
  • Alexanian R, Blacerzak S, Bonnet I: Prognostic factors in multiple myeloma. Cancer 1975; 36: 1192–1201
  • Cuzick J, Galton D AG, Peto R. Medical Research Council's Working Party on Leukemia in Adults): Treatment comparisons in the third MRC myelomatosis trial. Br J Cancer 1980; 42: 832–840
  • Case DC, Jr., Lee BJ JU, Clarkson B D: Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine, and BCNU: M-2 protocol. Am J Med 1977; 63: 897–903
  • Tirelli U, Crivellari D, Carbone A. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmestine (BCNU) (M-2 protocol). Cancer Treat Rep 1971–1973; 66, 1982
  • Lee B J, Lake-Lewis D, Myers J E. Intensive treatment of multiple myeloma. Controversies in Oncology, PH Wiernick. John Wiley, New York 1982; 61–79
  • Chronic Leukemia Myeloma Task Force National Institute Cancer. Proposed guidelines for protocol studies 11. Plasma cell myeloma. Cancer Chemother Rep 1973; 4: 145–158
  • Harley J B, Pajak T F, Mclntyre O R. Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: A study of the CALGB. Blood 1979; 54: 13–22
  • Bergsagel D E, Bailey A J, Langley G R. The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 1979; 301: 743–748
  • Medical Research Council's Working Party of Leukemia in Adults. Treatment comparisons in the third MRC myelomatosis trial. Br J Cancer 1980; 42: 823–830
  • Salmon S E, Haut A, Bonnet J D. Alternating combination chemotherapy improves survival in multiple myeloma: A Southwest Oncology Group study. J. Clin Oncol 1983; 1: 453–461
  • Durie B GM, Dixon D O, Carter S. Improved survival duration with combination chemotherapy induction for multiple myeloma: A Southwest Oncology Group study. In Process. J Clin Oncol 1986; 4: 1227–1237
  • Oken M M, Tsiatis A, Abramson N. Comparison of standard (MP) with intensive (VBMCP) therapy for the treatment of multiple myeloma (MM). (Abstract) Proc Am Sec Clin Oncol 1984; 3: 270
  • Coleman M, Silver R. Chemotherapy of plasma cell myeloma and related disorders. Antibiotics and Chemotherapy, HS Griemshed, RW Brockaw, FE Hon. Intercontinental Medical Book Corp., New York 1973; 103–136, Stratton
  • Case DC, Jr. Future prospects for the therapy of multiple myeloma. Cancer Invest 1989; 7: 243–246
  • McElwain T J, Powles P L. High-dose intravenous melphalan for plasma cell myeloma. Lancet 1983; 2: 822–824
  • Selby P J, McElwain T J, Nandi A C. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 1987; 66: 55–62
  • Richards F N, Coleman M, Cooper M R, Ballard W P. Multiple myeloma: Complete remission with high-dose melphalan. Chemother Cancer Invest 1985; 3: 15–21
  • Humphrey R L, Neville S V: High dose cyclophosphamide therapy of patients with poor risk myeloma. Am Soc Chem Oncol (abstr) 1978; 19: 410
  • Humphrey R L, Kvols L K, Braine H G, Abeloff M D. High dose Cytoxan therapy of poor risk myeloma and Waldenstrom's macroglobulinemia. Am Acad Cancer Res (abstr) 1973; 14: 54
  • Case DC, Jr., Coleman M, Gottlieb A: High dose melphalan (HDM) therapy for previously untreated Stage UJ multiple myeloma: a phase I-n study. Blood 1986; 65: 236a
  • Case DC, Jr., Coleman M, Gottlieb A. High dose melphalan (HDM) therapy for previously untreated Stage III multiple myeloma. Prac Am Soc Clin Oncol 1989; 8: 265
  • Durie B GM, Salmon S E. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842–854
  • Payne R E, Little A J, Williams R B. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 1973; 4: 643–646
  • MacLennan I CM, Cuzick J. for the MRC Working Party on leukemia in adults Objective evaluation of the role of vincristine in induction and maintenance for myelomatosis. Br J Cancer 1985; 52: 153–159
  • Greipp P R, Katzmann J A, O'Fallon W M. Value of B2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988; 782: 219–223
  • Cohen H J, Silberman H R, Forman W. Effects of age on responses to treatment and survival of patients with multiple myeloma. J Am Geriatr Soc 1983; 31: 272–277
  • Cohen H J, Bartolucci A. Age and the treatment of multiple myeloma. Am J Med 1985; 79: 316–324
  • Alexanian R, Jagannath S, Lemaistre F. High dose therapy (HDT) for multiple myeloma. Prac Am Soc Clin Oncol 1989; 8: 270
  • Gore M E, Mican S, Viner C. Continuous infusion of vincristine and adriamycin with high dose methylprednisolone (VAMP) followed by high dose melphalan (HDM) and autologous bone marrow transplantation in the treatment of myeloma. Prac Am Soc Clin Oncol 1989; 8: 252
  • Fermand J P, Levy Y, Gerota J. Treatment of aggressive multiple myeloma by dose-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood 1989; 73: 20–23
  • Harousseau J L, Milpied N, Garand R. High dose melphalan and autologous bone marrow transplantation in high risk myeloma. Br J Haematol 1987; 67: 493
  • Antman K S, Griffin JD. E, Iias A. Effect of recombined human granulocyte-macrophage colony stimulative factor in chemotherapy induced myelosuppression. N Engl J Med 1988; 319: 593–598
  • Barlogie B, Epstein J, Selvanayagaw P. Plasma cell myeloma–new biological insights and advances in therapy. Blood 1989; 73: 865–879
  • Durie B GM, Russell D H, Salmon S E. Reappraisal of plateau phase in myeloma. Lancet 1980; 2: 65–68

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.